证券代码：300404 证券简称：博济医药 公告编号：2025-070 博济医药科技股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《博济医药科技股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，经博济医药科技股份有限公司（以下简称"公司"或"本公司"）第 五届董事会第十六次会议审议通过，决议于 2025 年 9 月 12 日以现场投票与网 络投票相结合的方式召开公司 2025 年第一次临时股东大会，现将本次股东大会 有关事项通知如下： 一、 本次股东大会召开的基本情况 1、股东大会届次：2025 年第一次临时股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次会议的召开已经公司第五届董事会第十 六次会议审议通过，召集程序符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 9 月 12 日（星期五）下午 14:30。 （2）网络投票时间：2025 年 9 月 12 日。其中，通过深圳 ...

博济医药科技股份有限公司 第五届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十五次会 议于 2025 年 8 月 25 日在公司会议室召开，会议采取现场投票方式对议案进行表 决。本次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件、电话、微信等方 式发出。会议应到监事 3 人，实到 3 人。会议由监事会主席刘菁纯女士主持。本 次监事会的召集、召开符合《公司法》《公司章程》及相关法规的规定。 二、 监事会会议审议情况 1、 审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 证券代码：300404 证券简称：博济医药 公告编号：2025-066 表决结果：同意 3 票；反对 0 票；弃权 0 票。 3、 审议通过了《关于作废部分限制性股票的议案》 经审核，监事会一致认为：公司《2025 年半年度报告》及《2025 年半年度 报告摘要》的内容真实、准确、完整的反映了公司 2025 年半年度经营的实际情 况，不存在任何虚假记载、 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-065 本议案已经公司董事会审计委员会审议通过。 博济医药科技股份有限公司 第五届董事会第十六次会议决议公告 二、董事会会议审议情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、 审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 经审议，董事会一致认为：公司《2025 年半年度报告》及《2025 年半年度 报告摘要》符合法律法规、中国证监会和深圳证券交易所的相关规定，报告内容 真实、准确，完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 8 月 25 日在公司会议室召开，会议采取现场结合通讯投票的方式对 议案进行表决。本次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件、电话、 微信等方式发出。会议应到董事 7 人，实到 7 人，会议由董事长王廷春先生主持， 部分监事和部分高管列席了本次董事会。本次董事会的召集、召开符合《公司法》 《公司章程》及相关法 ...

Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to potential stricter NMPA drug approval requirements[3]. - The company aims to enhance its core competitiveness through strategic planning and layout, utilizing its full industry chain service advantages amid increasing competition in the domestic CRO market[6]. - The company is expanding its business into preclinical research services and CDMO services, facing potential risks due to competition and lack of experience in these new areas[8]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with the expansion of its operational scale and business scope[8]. - The company is committed to strengthening internal training and talent reserves to enhance its ability to withstand risks in the evolving regulatory environment[3]. - The company plans to enhance its risk management strategies in response to potential policy changes affecting new drug approvals and research investments[90]. - The company aims to expand its business into innovative drug clinical services and preclinical services to mitigate risks associated with market competition[91]. Financial Performance - The company's operating revenue for the reporting period reached RMB 361,448,457, representing a 5.88% increase compared to RMB 341,390,828.56 in the same period last year[25]. - The net profit attributable to shareholders decreased by 48.33% to RMB 15,569,864.27 from RMB 30,135,149.57 year-on-year[25]. - The net cash flow from operating activities significantly increased by 343.46%, amounting to RMB 21,245,267.43 compared to RMB 4,790,796.04 in the previous year[25]. - Total assets at the end of the reporting period were RMB 1,563,950,571.44, a 7.81% increase from RMB 1,450,592,225.50 at the end of the previous year[25]. - The company reported a basic earnings per share of RMB 0.0407, down 48.42% from RMB 0.0789 in the previous year[25]. - The company achieved total operating revenue of CNY 361,448,457, representing a year-on-year growth of 5.88%[39]. - Net profit attributable to shareholders decreased by 48.33% to CNY 15,569,864, while the net profit excluding non-recurring gains and losses fell by 53.28% to CNY 11,988,298[39]. Market Trends and Industry Insights - The global CRO market size grew from USD 59.2 billion to USD 92.7 billion over the past five years, with a projected CAGR of 9.93%[33]. - The Chinese CRO market is expected to reach RMB 118.3 billion in 2024, with a CAGR of approximately 20%[33]. - The clinical CRO market in China is projected to grow from RMB 26.3 billion in 2020 to RMB 83.5 billion by 2025, with a CAGR of 25.99%[33]. - The number of clinical trial applications accepted by the National Medical Products Administration increased from 1,830 in 2021 to 2,818 in 2024[34]. Operational Challenges and Risk Management - The company acknowledges the risks of contract execution delays in new drug development due to various factors, including clinical research failures and changes in client research directions[4]. - The company has established specific responsibility models in contracts to address potential delays and will conduct careful evaluations of project execution difficulties before accepting new projects[5]. - The company recognizes the need for improved budget management due to the long execution cycles of some innovative drug development contracts[4]. - The company will maintain good communication with clients to minimize the risks of cost overruns and insufficient profits during contract execution[5]. Research and Development - The company has filed for 8 invention patents, enhancing its core competitiveness through independent intellectual property rights[44]. - The company is advancing several innovative drug projects, including a new drug for chronic heart failure and a new drug for high uric acid levels, with significant progress reported[44]. - The company has established a comprehensive "one-stop" service capability for new drug development, significantly reducing time, research, communication, and conversion costs for clients[48]. Subsidiaries and Investments - The company has established a new subsidiary, Xinxin Traditional Chinese Medicine Technology, with no significant impact on overall operations and performance[89]. - The company has invested significantly in preclinical research capabilities, establishing a one-stop service platform with advanced technical features and advantages[51]. - The company has completed 100% of its promised investment in the R&D project as of the reporting date[78]. Corporate Governance and Compliance - The company emphasizes corporate governance and shareholder rights, ensuring compliance with relevant laws and regulations[107]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[111]. - There were no violations regarding external guarantees during the reporting period[112]. Shareholder Information and Stock Options - The company completed the third exercise period of the 2022 stock option incentive plan, with 1.1564 million stock options available for 60 incentive targets at an exercise price of 8.73 CNY per share[99]. - A total of 22.264 million stock options were canceled due to unexercised options from the second exercise period of the 2022 stock option incentive plan[100]. - The first vesting conditions of the 2023 restricted stock incentive plan were achieved, with 607,800 shares available for 39 incentive targets, and 458,400 shares were actually vested and listed for trading[101]. Related Party Transactions - The company engaged in related party transactions, including providing clinical research services valued at 21.42 million yuan, accounting for 0.52% of similar transaction amounts[118]. - Another related party transaction involved providing clinical research services valued at 290.57 million yuan, accounting for 1.00% of similar transaction amounts[118]. Future Outlook - The company plans to expand its market presence, focusing on new product development and technological advancements[190]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its portfolio[190].

Core Insights - Boji Pharmaceutical (300404) closed at 11.76 yuan on August 25, 2025, with a 3.43% increase and a turnover rate of 16.99% [1] - The company reported a total revenue of 139 million yuan for Q1 2025, a year-on-year decrease of 17.06%, and a net profit attributable to shareholders of 3.90 million yuan, down 76.38% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 139 million yuan, down 17.06% year-on-year [1] - Net profit for Q1 2025: 3.90 million yuan, down 76.38% year-on-year [1] - Non-recurring net profit: 1.70 million yuan, down 88.28% year-on-year [1] - Current ratio: 1.935, Quick ratio: 1.418, Debt-to-asset ratio: 31.99% [1] Market Activity - Main capital inflow: 18.48 million yuan, accounting for 3.32% of transaction volume [1] - Large orders net inflow: 19.49 million yuan, accounting for 3.5% of transaction volume [1] - Small orders net outflow: 23.88 million yuan, accounting for 4.29% of transaction volume [1] Company Background - Boji Pharmaceutical was established in 2002 and is located in Guangzhou, focusing on research and experimental development [2] - The company has invested in 39 enterprises and participated in 113 bidding projects [2] - Intellectual property includes 49 trademarks and 47 patents, along with 44 administrative licenses [2]

Group 1 - The fifth Shenzhen Biopharmaceutical Innovation Conference was held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The conference attracted nearly 3,500 participants, including around 200 industry experts and representatives, with over 3,300 attending via online streaming [1] - The global pharmaceutical industry is undergoing significant changes, with advancements in AI technology shortening drug development cycles and accelerating the internationalization of Chinese pharmaceutical companies [1] Group 2 - The founder of Yaoduo, Li Jing, highlighted that the export of Chinese innovative drugs has become a norm, with the License-out transaction amount expected to exceed 400 billion yuan in 2024, and the first payment nearing 36 billion yuan [2] - Emerging fields such as ADC, bispecific antibodies, and cell therapy are becoming highlights for Chinese companies going global, with a shift from "engineering manufacturing" to "original innovation" [2] - The global pharmaceutical market is projected to reach 19 trillion yuan by 2027, with oncology, autoimmune, and metabolic fields remaining key growth drivers [2] Group 3 - A roundtable discussion focused on the implementation of the Class B medical insurance catalog, emphasizing the importance of drug economic evaluation, real-world data sharing, and a one-stop settlement mechanism for innovative drugs to benefit Chinese patients [3] - The biopharmaceutical industry in China is transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation to gain a more significant position in the global pharmaceutical landscape [3] - The conference provided insights and practical strategies for the industry, facilitating efficient platforms for collaboration between enterprises and capital, as well as domestic and international partnerships [3]

Core Insights - The fifth Shenzhen Biopharmaceutical Innovation Conference was successfully held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Conference Overview - The conference adopted a dual-mode format of offline main venue and online live streaming, attracting nearly 3,500 participants, including industry experts, corporate representatives, and investors [1] - Keynote speeches and discussions centered around "new opportunities for biopharmaceutical innovation and going global," with significant participation from various stakeholders in the industry [1][2] Group 2: Key Themes and Discussions - The conference theme was "Leading Innovation Change, Insight into Transformation Pathways," focusing on the commercialization of innovative drugs and the dual circulation of internal and external markets [2] - The global pharmaceutical market is projected to reach $19 trillion by 2027, with oncology, autoimmune, and metabolic fields being the main growth drivers [2][3] - Challenges for companies going global include geopolitical issues, registration barriers, and commercialization difficulties, necessitating capabilities in market insight, efficient registration, channel coverage, academic support, and risk management [3] Group 3: Collaborative Efforts and Future Directions - The conference emphasized the need for collaboration among industry, academia, research, medicine, and investment sectors to build a globally competitive biopharmaceutical innovation ecosystem [2] - The discussions highlighted that the Chinese biopharmaceutical industry is at a critical stage of transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation [3]

证券代码：300404 证券简称：博济医药 公告编号：2025-063 博济医药科技股份有限公司 关于募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一） 募集资金的管理情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律、法规的规定，结合公司的实际情况，制 定了《募集资金管理制度》，对募集资金的存储、使用、用途变更及监督管理作 出了明确规定。 博济医药科技股份有限公司（以下简称"公司"或"博济医药"）2021 年向 特定对象发行股票的募集资金按照相关法律、法规和规范性文件的规定在银行开 立了募集资金专项账户。近日，公司办理完成了募集资金专项账户的注销手续， 现将具体情况公告如下： 二、募集资金存放和管理情况 本公司对募集资金实行专户存储，并对募集资金的使用执行严格的审批程序， 以保证专款专用。 1 2021 年，公司、全资子公司广州华圣制药有限公司（以下简称"华圣制药"， 原名"广州博济生物医药科技 ...

中国经济网北京8月22日讯博济医药（300404）(300404.SZ)昨晚披露关于控股股东及其一致行动人减持股份预披露公告 称，公司于近日收到控股股东、实际控制人王廷春及其一致行动人横琴广金美好基金管理有限公司-广金美好费米十三 号私募证券投资基金(以下简称"费米十三号")出具的《股份减持计划告知函》。 据新浪财经数据显示，王廷春最初持股2585.5万股，占总股本的38.78%。王廷春从2019年5月21日起，第一次减持博济 医药股份，迄今为止，累计减持公司股票909.67万股，累计套现约1.51亿元。 | 減持期间 | | 减持均价（元/股）减持股数(万股) 套现金额(万元) 减持后持股比例 | | | --- | --- | --- | --- | | 20211116-20211116 13.96 | 18.95 | 264.54 | 29.22% | | 20211115-20211115 13.62 | 26.45 | 360.25 | 29.29% | | 20211112-20211112 13.3 | 28.86 | 383.84 | 29.39% | | 20211111-20211111 ...

Economic Information - According to the China Index Academy, as of August 2025, the debt restructuring and reorganization of 20 distressed real estate companies will exceed 12,000 billion RMB, significantly impacting the real estate sector [2] - As of August 13, the national pig price was 14.25 RMB/kg, down 1.32% from August 6, with the pig-to-grain price ratio at 5.94, a decrease of 1.33% [2] Company Alerts - Jishi Media reported a net loss of 232 million RMB in the first half of the year [5] - Dameng Data had two directors investigated within three days [5] - Kanglong Chemical's net profit for the first half of the year was 701 million RMB, a decrease of 37% year-on-year [5] - Yunmei Energy reported a net loss of 163 million RMB in the first half of the year [5] - Zhuosheng Microelectronics experienced a net loss of 147 million RMB in the first half, marking a transition from profit to loss [5] - Penghui Energy reported a net loss of 88.23 million RMB in the first half, also transitioning from profit to loss [5] - Aoxin Security reported a net loss of 356 million RMB in the first half [5] - Anyuan Coal Industry reported a net loss of 290 million RMB in the first half [5] - Guangsheng Tang reported a net loss of 66.6881 million RMB in the first half [5] - Yiyuan Lithium Energy's net profit decreased by 24.9% year-on-year in the first half [5] - Zhongtian Rocket's net profit decreased by 80.74% year-on-year in the first half [5] - Jianjie Industrial reported a net profit of 48.8658 million RMB in the first half, down 44.90% year-on-year [5] - Nanjing Chemical Fiber reported a net loss of 88.9317 million RMB in the first half [5] - Sanwei Xinan reported a net loss of 29.3858 million RMB in the first half [5] - Taiping Bird reported a net profit of 77.7116 million RMB in the first half, down 54.61% year-on-year [5] - Aerospace Power reported a net loss of 73.1243 million RMB in the first half [5] - Renhe Pharmaceutical's subsidiary product ULook brain-machine interaction smart glasses has not generated sales revenue [5] - Rhein Biotech experienced a safety incident resulting in one death and three serious injuries [5] - Guangfeng Technology's arbitration ruling is expected to reduce the consolidated profit for 2025 by approximately 91 million RMB [5] Overseas Alerts - The three major U.S. stock indices experienced slight declines, with the S&P 500 down 0.4%, marking its fifth consecutive day of decline [4] - The U.S. Department of Justice plans to investigate Federal Reserve Governor Lisa Cook and has urged Fed Chairman Powell to dismiss her [4] - According to the International Copper Study Group, a surplus of 36,000 tons in the global refined copper market is expected by June 2025 [4]